Eton Pharmaceutcials Inc (ETON) valuation
Eton Pharmaceutcials P/E ratio history
Eton Pharmaceutcials trades at 133.8 times its earnings over the last twelve months and 26.4 times the earnings analysts expect over the next twelve.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Dec 31, 2025 | $16.91 | -$0.17 | n/m |
| Dec 31, 2024 | $13.32 | -$0.15 | n/m |
| Dec 31, 2023 | $4.38 | -$0.04 | n/m |
| Dec 31, 2022 | $2.82 | -$0.36 | n/m |
| Dec 31, 2021 | $4.29 | -$0.08 | n/m |
| Dec 31, 2020 | $8.13 | -$1.36 | n/m |
| Dec 31, 2019 | $7.20 | -$1.03 | n/m |
| Dec 31, 2018 | $6.12 | -$5.89 | n/m |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Eton Pharmaceutcials valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Eton PharmaceutcialsETON | $1.43B | 133.8 | 26.4 | 13.5 |
| Pacira BiosciencesPCRX | $1.43B | 101.1 | 11.5 | 1.9 |
| Agilon HealthAGL | $1.42B | — | 77.3 | 0.2 |
| Pennant GroupPNTG | $1.45B | 45.8 | 27.9 | 1.3 |
| AnaptysbioANAB | $1.41B | — | 10.8 | 5.9 |
| Nutex HealthNUTX | $1.38B | 7.7 | 7.3 | 1.6 |
| Mineralys TherapeuticsMLYS | $1.50B | — | — | — |
| Alignment HealthcareALHC | $1.51B | 36.4 | 13.8 | 0.3 |
| Ocular TherapeutixOCUL | $1.53B | — | — | 29.3 |
| Peer median | 41.1 | 12.6 | 1.6 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: ETON financials · ETON returns
No forecast, no recommendation. This page describes Eton Pharmaceutcials Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.